International Journal of Gynecological Cancer (IJGC), the official journal of the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a multidisciplinary approach, and includes original research, reviews, and video articles. The audience consists of gynecologists, medical oncologists, radiation oncologists, radiologists, pathologists, and research scientists with a special interest in gynecological oncology.
Questions? Contact email@example.com
Institutional Review Board Approval
Every research article, including every submitted article involving human participants, requires a statement of ethical or institutional review board approval within the manuscript text. Furthermore, a formal letter of ethical or institutional review board approval must be uploaded along with the manuscript files at initial submission. Find more information about ethical approval.
When submitting a revision, please include an Author’s Response to the reviewers’ comments. Please list each comment from each reviewer and provide a point-by-point response indicating how the comment has been addressed and the specific page(s) and line number(s) where the change was made in the manuscript text file. Additionally, please copy and paste the changed text in the Author’s Response.
An example is below:
Reviewer 1, Comment 1: Please clarify what you mean by “borderline pathology.”
Author’s Reply: We have clarified this in the Methods section on page 6, lines 4-5.
Modified Text: “Patients with borderline mucinous and serous tumors were more likely to be partially satisfied, not satisfied or not at all satisfied compared to patients with cancer (p=0.027).”
Please note that authors may be required to provide data or cited works upon request for purposes of peer review.
Please note the following regarding the use of abbreviations for IJGC.
Abbreviations are always allowed for:
- Units of measure
- Clinical trial names
- Any name of a gene (e.g., BRCA) or serologic market (e.g., CA125)
Abbreviations are allowed but must be spelled out at first use for:
- Statistical terms (SPSS, Stata)
- The following organizations: NCI, WHO, FDA, CDC
- The following terms: HPV, Pap, MRI, USG, CT, PET/CT, HNPCC, HIPEC, RIFLE, FDG, EGOG, SLN, NCCN, FIGO, AUC, VIN, dVIN, HSIL, STIC, EOC, HGSC, and SCS
Abbreviations cannot be used – and must be spelled out at each use for the following: UVA, MAV, DFS,
PFS, OS, OCCC, CRS, PCI, AKI, PCN, IRIS
The word count excludes the title page, abstract, tables, acknowledgements and contributions and the references. If you are not a native English speaker and would like assistance with your article there is a professional editing service available.
The IJGC is not currently accepting submissions on breast cancer. Additionally, given the high volume of submissions on the subject of HPV and pre-invasive disease of the lower genital tract, we will restrict consideration for review and ultimate publication to those manuscripts reflecting novel data from either large prospective trials or high-level scientific multi-institutional efforts reflecting a high number of patients. We will also give higher priority to work that is impacting a segment or region of the world where HPV has been limited. Manuscripts reflecting findings that have already been published by others with similar results will not be considered for review and will be returned to authors.
When a paper has been submitted from the Editor, Deputy or Associate Editors’ departments, they have no role in the reviewing or decision-making process. This also applies to any Associate Editors who are authors, in which instance the reviewing process is handled by the Editor in Chief.
The IJGC encourages the submission of manuscripts outlining results of research conducted in collaboration and/or supported by industry partnership. Manuscripts where authorship is shared among investigators both involved or uninvolved with industry sponsors will be evaluated in detail for compliance with updated Conflict of Interest statements. In addition, the number of authors who are directly or indirectly strictly linked with a company or pharmaceutical will be limited to no more than two authors. All authors must be in agreement with the final submission of such manuscript, and such authors shall agree to provide raw data if so requested by either Editorial team or Reviewers. Manuscripts exclusively written by members of a pharmaceutical company without any input from medical/surgical collaborators will not be considered for review.
When submitting to IJGC, please ensure all files are submitted correctly with the corresponding file types selected. Doing so can help reduce the amount of time before your paper receives a decision.
- All tables should be submitted in the manuscript document after the references section. The main manuscript document (with tables) file should be in Word doc format.
- Each figure should be uploaded as a separate “Image” file. Figures may be in TIFF, EPS, PDF, or JPEG format.
- Highlights should be uploaded in one “Highlights” file. The Highlights document should be in Word doc format.
It should appear after the paragraph beginning “When a paper has been submitted from the Editor” and before the Author Guide video.
Our intent is to publish high quality research as it relates to clinical trials, outcome analyses, translational research, cost utility analyses, etc. Meta-analyses and literature reviews should be submitted as Original Articles and require a PRISMA Checklist. Authors should use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for grading evidence when submitting a clinical guidelines article.
Original research should include a structured abstract of no more than 300 words with the following subsections: Introduction, Methods, Results and Discussion. The manuscript text should have the following headings: Introduction, Methods, Results and Discussion.
Original research should also include a Precis of 200 characters, which should briefly provide information on the value and impact of the study. Authors should also submit 3 Highlights of no more than 100 characters each, outlining the key findings and impact of the study. Authors may also include supplemental figures and tables.
Word Count: up to 2,700 words
Abstract: up to 300 words
Tables/Figures: up to 5 tables and/or figures
References: up to 35
Authors: up to 40 (no more than 8 from a single institution)
Review articles will address a topic of major interest in the field of gynecologic oncology and should include an unstructured abstract of no more than 300 words and a Precis of no more than 200 characters. The Precis should briefly provide information on the value and impact of the study. Authors may also include supplemental figures and tables.
Abstract: up to 300 words
Word Count: up to 5,000 words
Tables/Figures: up to 7 tables and/or figures
References: up to 50
Authors: up to 5
By invitation only, Case Studies include a specific case of interest in the field of gynecologic oncology, a question and answer, and a discussion. They are limited to five authors total with two presenters, one discussant, one pathologist, and one radiologist.
Word Count: up to 2,500
Tables/Figures: up to 1 table and 4 figures
References: up to 10 references
Authors: up to 5
Letters should be a short and concise communication commenting on a recently published Original Article in the Journal or commenting on a controversial current issue of concern to the readership. The letters must be submitted within 1 month of publication of the Original Article in question. A Letter to the Editor is not a site for publication of original results. A statement of potential sources of conflict of interest must accompany the letter and may be published along with the letter. The Editorial Board reserves the right to decline publishing insulting or inflammatory comments in letters to the editor.
Word Count: up to 200
References: up to 5
Authors: up to 3
By invitation, Editorials have a limit of 500 words and a limit of 2 authors, and 5 references, including the article in question.
Word count: up to 500
References: up to 5
Authors: up to 2
This exciting new feature focuses on high-quality videos that includes any educational topic in Gynecologic Oncology. IJGC’s aim is to provide gynecologic oncologists around the world with a unique educational opportunity using multimedia. Video articles may focus on radiological imaging, ambulatory procedures, pathology, surgical anatomy, exposure, innovation, reconstruction, step-by-step-procedures, complications and resolutions, as well as anatomic variations, tips and tricks in gynecologic oncology, robotics, or new devices. Video Articles may also illustrate ways of improving surgery in developing countries or implementing surgery in scenarios with low resources. Videos that have been presented at a meeting are eligible to be submitted to IJGC.
A video article should include a video that is between 5 and 8 minutes in duration and no larger than 350 MB. The video must be narrated in English and should not include music. The video may include slides, not exceeding 2 minutes in total. The first slide of the video must include the submission title and the authors’ name(s) and institution(s). The last slide of the video must include the conclusions and acknowledgments. Whenever a video article shows a surgical procedure, it is recommend to add within the video (or as supplementary material) two tables showing the specific material needed and a summary of tips for carrying out the procedure. An individual high quality still image of the video should also be submitted that illustrates the technique demonstrated in the video. Additionally, the manuscript text should only be an unstructured summary of no more than 350 words, and must include references, no more than 4. Please list the length (in minutes), the size (in megabytes), and the type of video file (.mov, .mpg, .avi, or .mp4) in the title page. Video articles have a limit of 6 authors.
We encourage authors to include text and drawings in the video showing and pointing out the anatomical structures as well as schemas either of the procedure or the surgical field. Attractive educational content along with a high quality video and sound are greatly appreciated at the time of the evaluation. Authors are encouraged to contact IJGC’s Video Editor Luis Chiva (firstname.lastname@example.org) for any questions or assistance with creating a Video Article.
Summary: up to 350 words
References: up to 4
Authors: up to 6
Length: up to 8 minutes
File size: up to 350 MB
These articles will look at ongoing clinical trials in the field of gynecologic oncology. The articles must have a main objective and the studies must have and/or be accruing patients. The articles should include an Introduction, explaining the rationale for the study; a Methods section (inclusion and exclusion criteria for the study must be clearly outlined), detailing the study design; and a Discussion section, describing how the study may change current standards of care and practice. Authors may also include supplemental figures and tables.
Word Count: up to 2,500 words
Tables/Figures: up to 5 tables and/or figures
References: up to 15
Authors: up to 30
Detailed instructions are below:
Please use all of the subheadings listed below.
- Background (2 sentences)
- Primary Objective(s) (1-2 sentences). Please do not include secondary/exploratory objectives in abstract
- Study Hypothesis (1 sentence)
- Trial Design (3-4 sentences)
- Major Inclusion/Exclusion Criteria (2-3 sentences)
- Primary Endpoint(s) (1-2 sentence)
- Sample Size
- Estimated Dates for Completing Accrual and Presenting Results
- Trial Registration
- Should include brief background, rationale, and hypothesis (3-4 paragraphs)
Trial Design (Subheading)
- Description of trial design/treatment plan
- Include funding source (if applicable)
- Setting including participating organizations and number of sites
- Include study schema as a figure
- Inclusion/exclusion criteria (major)
- Can be more detail than abstract but do not get into minutia
Primary Endpoints (Subheading)
- Include primary and secondary objective(s) and endpoints
- Important translational/exploratory endpoints (but not all)
Sample Size (Subheading)
- How sample size was determined
- When applicable, explanation of any interim analyses and stopping guidelines
Randomization and blinding (Subheading) (if applicable)
- Method used to generate the random allocation sequence
- Type of randomization
- If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how
Statistical Methods (Subheading)
- Brief details of analysis of primary and secondary endpoints (1-2 paragraphs)
- Brief summary of expected results and how they will change practice
A brief article highlighted those in the field of gynecologic oncology who are doing impactful work in either their local community or abroad. IJGC‘s goal is to show the global scope of our mission and to excite other who are doing great work. Though there is a limit of 5 authors for the article, an Acknowledgements list for those involved in the work may be included.
Word Count: up to 500 words
Tables/Figures: up to 3 figures
References: up to 5
IJGC aims to operate a fast submission and review process, to ensure timely, up-to-date research is available worldwide. Submissions should be made through the Journal’s online submission system, here. Articles should not be under review by any other journal when submitted to IJGC.
IJGC adheres to the highest standards concerning its editorial policies on publication ethics, scientific misconduct, consent and peer review criteria. To view all BMJ Journal policies please refer to the BMJ Author Hub policies page.
Peer review may seem like a thankless task, but without it research would be unreliable. IJGC and BMJ value reviewers and want to encourage good standards of review. We encourage reviewers to read the Reviewer Guide or view the video below to learn more as Dr. Pedro Ramirez, IJGC’s Editor-in-Chief, provides reviewers with detailed instructions and considerations for preparing review comments for IJGC manuscripts.
During submission, authors can choose to have their article published open access. There are no submission, page or color figure charges. The costs for open access for members are $2,200 and for non-members the costs are $2,800.
For more information on open access, funder compliance and institutional programs please refer to the BMJ Author Hub open access page.
Your article will not automatically be transferred to IJGC if rejected from another BMJ Journal; however, you will be able to choose IJGC as an alternate journal when submitting an article to any BMJ Journal; any reviewer comments will be shared, resulting in a reduced time to decision.
Manuscripts will be evaluated separately by the IJGC editorial team, with different criteria for acceptance.
BMJ is a member of CrossCheck by CrossRef and iThenticate. iThenticate is a plagiarism screening service that verifies the originality of content submitted before publication. iThenticate checks submissions against millions of published research papers, and billions of web content. Authors, researchers and freelancers can also use iThenticate to screen their work before submission by visiting ithenticate.com.
Authors of original research articles are encouraged to include a data sharing statement when submitting their article. The statement should explain which additional unpublished data from the study—if any—are available, to whom, and how these can be obtained.
At present there is no major repository for clinical data, but Dryad has declared its willingness to accept medical datasets. Authors can start the deposition process while submitting to any BMJ Journal. Dryad provides authors with a DOI for the dataset to aid citation and provide a permanent link to the data. Note that Dryad hosts data using a CC0 license so authors should check that this is suitable for the data that they are depositing. The DataCite organization has a growing list of other repositories for research data.
IJGC mandates ORCID IDs for the submitting author at the time of article submission; co-authors and reviewers are strongly encouraged to also connect their ScholarOne accounts to ORCID. We strongly believe that the increased use and integration of ORCID iDs will be beneficial for the whole research community. Please find more information about ORCID and BMJ’s policy on our Author Hub.
The BMJ Publishing Group journals are willing to consider publishing supplements to regular issues. Supplement proposals may be made at the request of:
- The journal editor, an editorial board member or a learned society may wish to organise a meeting, sponsorship may be sought and the proceedings published as a supplement.
- The journal editor, editorial board member or learned society may wish to commission a supplement on a particular theme or topic. Again, sponsorship may be sought.
- The BMJPG itself may have proposals for supplements where sponsorship may be necessary.
- A sponsoring organisation, often a pharmaceutical company or a charitable foundation, that wishes to arrange a meeting, the proceedings of which will be published as a supplement.
In all cases, it is vital that the journal’s integrity, independence and academic reputation is not compromised in any way.
For further information on criteria that must be fulfilled, download the supplements guidelines.
When contacting us regarding a potential supplement, please include as much of the information below as possible.
- Journal in which you would like the supplement published
- Title of supplement and/or meeting on which it is based
- Date of meeting on which it is based
- Proposed table of contents with provisional article titles and proposed authors
- An indication of whether authors have agreed to participate
- Sponsor information including any relevant deadlines
- An indication of the expected length of each paper Guest Editor proposals if appropriate